Your IP : 172.28.240.42
<!DOCTYPE html>
<html class="no-js" lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title></title>
<meta name="description" content="">
<!-- Inlined critical CSS -->
<style>@font-face{font-weight:400;font-family:Roboto;font-style:normal;src:url(/t/spc/fonts/) format("woff2"),url(/t/spc/fonts/) format("woff");font-display:swap;unicode-range:U+000-5FF}@font-face{font-weight:400;font-family:Roboto;font-style:italic;src:url(/t/spc/fonts/) format("woff2"),url(/t/spc/fonts/) format("woff");font-display:swap;unicode-range:U+000-5FF}@font-face{font-weight:500;font-family:Roboto;font-style:normal;src:url(/t/spc/fonts/) format("woff2"),url(/t/spc/fonts/) format("woff");font-display:swap;unicode-range:U+000-5FF}@font-face{font-weight:700;font-family:Roboto;font-style:normal;src:url(/t/spc/fonts/) format("woff2"),url(/t/spc/fonts/) format("woff");font-display:swap;unicode-range:U+000-5FF}*,::after,::before{-webkit-box-sizing:border-box;box-sizing:border-box}body,html{height:100%}body{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-ms-flex-direction:column;flex-direction:column;width:100%;min-width:320px;height:100vh;margin:0 auto;font-weight:400;font-size:18px;line-height:1.5;font-family:Roboto,sans-serif;color:#132331}ol,ul{margin:0;padding:0}.button{display:inline-block;color:#fff;text-decoration:none;white-space:nowrap;border:2px solid #ff7a00;border-radius:92px;-webkit-transition:background .2s ease-out;transition:background .2s ease-out}.button:focus,.button:hover{color:#fff;text-decoration:none;border:2px solid #f89f4d}.button--primary{padding:7px 45px;background:0 0}.button--secondary{padding:10px 80px;font-size:20px;line-height:36px;background:#ff7a00}.button--secondary:focus,.button--secondary:hover{background:#f89f4d}.button--chat{width:86px;height:82px;margin:0 0 15px;background-color:transparent;background-image:url(/t/spc/img/);background-size:100% auto;border:none;border-radius:0;outline:0}.button--chat:focus,.button--chat:hover{border:none;opacity:.7}.button--add{padding:20px 77px;font-weight:700;color:#132331;text-transform:capitalize}.button--add:focus,.button--add:hover{color:rgba(19,35,49,.7)}.wrapper{position:relative;display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-flex:1;-ms-flex:1 0 auto;flex:1 0 auto;-webkit-box-orient:vertical;-webkit-box-direction:normal;-ms-flex-direction:column;flex-direction:column;min-height:100vh;min-height:calc(100 * var(--vh,1vh));overflow-x:hidden}.header{position:absolute;top:0;right:0;left:0;z-index:999;min-width:320px;padding:30px 0;background-color:#132331;-webkit-transition:height .3s ease-out,background .3s ease-out;transition:height .3s ease-out,background .3s ease-out}.header .container{position:relative;display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;height:100%}.header .navbar-toggle{position:relative;margin:0 0 0 auto;padding:0;background:0 0;border:none;border-radius:0;width:30px;height:20px}.header .navbar-toggle::after,.header .navbar-toggle::before{content:"";position:absolute}.header .navbar-toggle::before{top:8px;opacity:1}.header .navbar-toggle::after{top:50%;left:50%;-webkit-transform:translate(-50%,-50%);transform:translate(-50%,-50%);width:44px;height:44px}.header .navbar-toggle span{position:absolute;-webkit-transform-origin:right;transform-origin:right}.header .navbar-toggle span:first-of-type{top:0}.header .navbar-toggle span:last-of-type{bottom:0}.header .navbar-toggle span,.header .navbar-toggle::before{right:0;left:0;height:3px;background:#ff7a00;-webkit-transition:.15s;transition:.15s}.header .navbar-toggle:not(.collapsed)::before{opacity:0}.header .navbar-toggle:not(.collapsed) span:first-of-type{top:-2px;-webkit-transform:rotate(-45deg);transform:rotate(-45deg)}.header .navbar-toggle:not(.collapsed) span:last-of-type{bottom:-2px;-webkit-transform:rotate(45deg);transform:rotate(45deg)}.header--scrolled{position:fixed;top:0;right:0;left:0;z-index:999;background:#132331;-webkit-box-shadow:0 1px 5px rgba(0,0,0,.1);box-shadow:0 1px 5px rgba(0,0,0,.1)}.header--scrolled .main-menu__btn-wrapper .button--order{background:#ff7a00}.auth_mode .header--scrolled{top:34px}.main-menu{position:absolute;top:90px;right:0;left:0;z-index:1;margin:0;padding:0 0 50px;text-align:center;background:#132331;border:0;-webkit-box-shadow:0 13px 13px 5px rgba(112,112,112,.16);box-shadow:0 13px 13px 5px rgba(112,112,112,.16);visibility:visible}.main-menu .nav{margin:0;padding:20px 0 30px}.main-menu .nav li{margin:0 30px;list-style:none}.main-menu .nav a{padding:10px 0;line-height:;color:#fff;text-shadow:none;outline:0;-webkit-transition:color .15s;transition:color .15s}.main-menu__btn-wrapper{padding:0 0 25px}.main-menu__btn-wrapper li{margin:25px auto 0;list-style:none}.main-menu__btn-wrapper li:nth-of-type(n+2) a:hover{background:#ff7a00;border:2px solid #ff7a00}.main-menu__btn-wrapper a{min-width:177px}.main-menu .active a:not(.button),.main-menu .nav a:focus,.main-menu .nav a:hover{color:#ff7a00;background:0 0}.main-menu .active a{color:#ff7a00}.intro{padding:142px 0 40px;color:#fff;background-color:#132331}.intro h1{margin:0;font-weight:700;font-size:36px;line-height:54px}.intro p{width:95%;margin:0 0 23px}.intro p:last-of-type{margin:0 0 72px}.intro .container{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-ms-flex-direction:column;flex-direction:column;-ms-flex-wrap:wrap;flex-wrap:wrap;-webkit-box-align:center;-ms-flex-align:center;align-items:center;text-align:center}.intro .button{margin:0 0 40px}.strengths{padding:92px 0 80px}.strengths .container{position:relative}.strengths h2+p{width:94%;margin:0 auto 33px;text-align:center}.strengths__list{margin:0;padding:0;list-style:none}.strengths__list h3{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-align:center;-ms-flex-align:center;align-items:center;margin:0 0 5px;padding:0;font-weight:500;font-size:18px;line-height:29px;text-transform:uppercase}.strengths__list h3::before{content:"";margin:0 10px 0 0;background-repeat:no-repeat}.strengths__item{margin:28px 0 0}.strengths__item--terms h3::before{width:42px;height:44px;background-image:url(data:image/svg+xml,%3Csvg%20width%3D%2243%22%20height%3D%2245%22%20fill%3D%22none%22%20xmlns%3D%22http%3A%2F%%2F2000%2Fsvg%22%3E%3Cpath%20d%3D%%%%%%%200%%%%%%%%200%%%%%%%%200%%22%20fill%3D%22%23FF7A00%22%2F%3E%3Cpath%20d%3D%%%%%%%200%%%%%%200%20010%%%%%%200%%%%%%%200%%%%%200%%%22%20fill%3D%22%23FF7A00%22%2F%3E%3Cpath%20d%3D%%%200%%200%%%%200%%%%200%%200%%200%%%%%200%%200%%200%%200%%%%200%%%%200%%200%%%%200%%200%%%200%20000%%200%%200%%%200%%%%%200%%%%200%%%%%%%200%%200%%%%200%%%%200%%%%200%%200%%%%200%%%200%%%%%%%200%%200%%%%%200%%200%%200%%%200%20010%%200%%%%200%%%%%%%%%%%200%%%%%%200%%%%200%%%22%20fill%3D%22%23FF7A00%22%2F%3E%3Cpath%20d%3D%%%200%%200%%200%%%200%%%%%200%%%%200%%%%200%%%%%200%%%200%%%200%%22%20fill%3D%22%23FF7A00%22%2F%3E%3C%2Fsvg%3E)}.strengths__item--rich h3::before{width:35px;height:44px;background-image:url(data:image/svg+xml,%3Csvg%20width%3D%2234%22%20height%3D%2245%22%20fill%3D%22none%22%20xmlns%3D%22http%3A%2F%%2F2000%2Fsvg%22%3E%3Cpath%20d%3D%%%%%%%%%200%%%%%%%%200%%%%%%%%%%%%%%%%22%20fill%3D%22%23FF7A00%22%2F%3E%3Cpath%20d%3D%%%%%200%%%%200%%%200%%%200%%%%200%%%200%%%%200%%%200%%%200%%%%200%%%200%%200%%200%%200z%22%20fill%3D%22%23FF7A00%22%2F%3E%3Cpath%20d%3D%%%200%20000%%%%%%%%200%%%%%200%%%%200%%%%200%%%200%%%200%%200%%%%%200%%%%%%%%%%200%%%200%%%%%200%%%%200%%%%200%%%22%20fill%3D%22%23FF7A00%22%2F%3E%3C%2Fsvg%3E)}.strengths__item--result h3::before{width:33px;height:38px;background-image:url(data:image/svg+xml,%3Csvg%20width%3D%2234%22%20height%3D%2239%22%20fill%3D%22none%22%20xmlns%3D%22http%3A%2F%%2F2000%2Fsvg%22%3E%3Cpath%20d%3D%%%%200%%%200%%%%200%20000%%%200%%%200%%%200%%%200%%%200%%%200%%22%20fill%3D%22%23FF7A00%22%2F%3E%3Cpath%20d%3D%%%%200%%%%200%%200%%200%%200%%%%%200%%%%200%%%%%200%%%%200%%%%%200%%%%%%200%%200%%%200%%200%%%200%20000%%200%%%%%200%%%%%%%200%%%%200%%%%200%%%200%%%%200%%%%200%%%%200%%%%%%200%%200%%200%%200%%%200%%200%%200%%%200%%%200%%200%%200%%%200%%200%%200%%%200%%%%200%%200%%%%200%%200%%%200%%%%%200%%%200%%%200%%200%%%200%%%%200%%200%%200%%%200%20000%%%200%%200%%200%%200%%%%200%%200%%22%20fill%3D%22%23FF7A00%22%2F%3E%3C%2Fsvg%3E)}.strengths--alt ul li p{text-align:center}.strengths--alt ul li p span{color:#ff7a00;font-weight:700;font-size:26px}@media (min-width:768px){.header .container{width:100%;max-width:1170px}}@media screen and (min-width:768px){.header .navbar-toggle{display:block}.main-menu{right:0;left:auto;width:100%;-webkit-box-shadow:0 13px 13px 0 rgba(112,112,112,.16);box-shadow:0 13px 13px 0 rgba(112,112,112,.16)}.main-menu .nav,.main-menu .nav li{float:none}}@media screen and (min-width:992px){.button--secondary{padding:10px 100px}.header{padding:20px 0}.header .navbar-toggle{display:none}.main-menu{position:relative;top:auto;display:-webkit-box!important;display:-ms-flexbox!important;display:flex!important;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-ms-flex-align:center;align-items:center;width:auto;height:auto;margin-left:auto;padding:0;background:0 0;-webkit-box-shadow:none;box-shadow:none}.main-menu .nav{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;padding:0}.main-menu .nav li{margin-right:0;margin-left:0}.main-menu .nav li:nth-of-type(1n+2){margin-left:15px;border-top:none}.main-menu .nav a{font-size:16px}.main-menu__btn-wrapper{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-ms-flex-align:center;align-items:center;margin:0 0 0 15px;padding:0}.main-menu__btn-wrapper li{margin:0}.main-menu__btn-wrapper li:nth-of-type(n+2){margin-left:10px}.main-menu__btn-wrapper a{min-width:140px}.intro h1{width:66%;max-width:752px;margin:75px 0 27px;font-size:50px;line-height:60px}.intro p{width:51%;max-width:580px}.intro .container{-webkit-box-align:start;-ms-flex-align:start;align-items:flex-start;text-align:left}.intro .container .button-scroll-down{-ms-flex-item-align:center;align-self:center}.strengths{padding:75px 0 85px}.strengths h2{max-width:530px;margin:0 auto 23px}.strengths h2+p{max-width:745px;margin:0 auto 35px}.strengths__list{display:-webkit-box;display:-ms-flexbox;display:flex;-webkit-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between}.strengths__list h3{margin:0 0 10px}.strengths__item{max-width:325px;margin:28px 50px 0 0}.strengths__item:last-of-type{margin:28px 0 0}}@media (min-width:992px){.header img{width:158px;height:66px}.intro .button{margin:-27px 0 0}.intro{margin:106px 0 0;padding:30px 0 50px;color:#fff;background-image:url(/t/spc/img/bg@);background-repeat:no-repeat;background-position:center center;background-size:cover}}@media (min-width:992px) and (-webkit-min-device-pixel-ratio:1.5),(min-width:992px) and (min-resolution:144dpi),(min-width:992px) and (min-resolution:){.intro{background-image:url(/t/spc/img/bg@)}}@media screen and (min-width:1200px){.main-menu .nav li:nth-of-type(1n+2){margin-left:25px}.main-menu .nav a{margin-left:18px}.main-menu__btn-wrapper{margin:0 0 0 25px}.main-menu__btn-wrapper a{min-width:180px}}@media screen and (max-width:12450px){.intro--alt,.intro--blog{margin:0;padding:30px 0 90px;background:#132331}}</style><!-- Favicons -->
<link rel="apple-touch-icon" sizes="180x180" href="/t/spc/img/favicons/">
<meta name="msapplication-TileColor" content="#da532c">
</head>
<body class="">
<br>
<div class="wrapper"><!-- /.header -->
<div id="info-block" aria-label="info-block"></div>
<!-- .intro -->
<section class="intro intro--blog"></section><!-- /.intro -->
<!-- .page-content -->
<div class="page-content page-content--post">
<div class="container">
<main class="page-content__main page-content__main--post">
</main>
<div id="blog_detail">
<h1 id="90-impromptu-speech-topics-ideas">Steroids in covid. In this systematic review, we .</h1>
<div class="post_data"> </div>
<div class="item">
<h2><br>
</h2>
<p><img alt="AD_4nXcbGJwhp0xu-dYOFjMHURlQmEBciXpX2af6" src="width=" 623="" height="413"></p>
<p>Steroids in covid. Patients older than 70 years, independent of illness severity, chronic neurological disease, and dementia, were less likely to receive corticosteroids than those who were younger, as were pregnant women. Steroid use for COVID-19 COVID-19 (+) patients with asthma exacerbations Recommend use of corticosteroids, per the asthma pathway. Sep 2, 2020 · WHO also partnered with investigators of seven trials on corticosteroids to conduct a prospective meta-analysis of randomized trials for corticosteroid therapy for COVID-19 (PMA), in order to rapidly provide additional evidence to build on RECOVERY data and inform guidance development. Corticosteroids in COVID-19: guideline development process (1/2) In July 2020, WHO partnered with principal investigators of 7 corticosteroid trials and formed the Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group to conduct a prospective meta-analysis (PMA) of randomized trials for corticosteroid therapy for COVID- 19. In anticipation, an elderly man self-medicated himself with dexamethasone on the day of symptom onset of a flu-like illness, took other symptomatic measures and was tested Sep 2, 2020 · Overall, the meta-analysis indicates that administration of steroids is clearly associated with benefit among critically ill patients with COVID-19, although the exact threshold at which an individual patient should be prescribed corticosteroids remains unclear. Feb 24, 2023 · Independent of severity of illness, it is also likely that patient characteristics such as age and medical comorbidity, dose and type of steroid, timing of steroid initiation, and duration of steroid administration also influence the impact of systemic corticosteroids in COVID-19 patients. ” Again, most of these studies addressed only one severity COVID‑19 is the syndrome caused by a novel coronavirus, SARS-CoV‑2, which was originally detected late 2019 in Wuhan, Hubei Province, China. May 8, 2025 · Prolonged steroid therapy beyond 10 days did not improve survival or other clinical outcomes in patients with severe COVID-19, suggesting that early steroid withdrawal may be appropriate for selected patients. Strongyloides and amebic infections are neglected diseases that can progress to catastrophic Apr 8, 2022 · This study uses 2 large US health care claims databases (Medicare fee-for-service and the US Food and Drug Administration’s Sentinel System) to examine systemic corticosteroid use among nonhospitalized patients with COVID-19. However, the use of steroids in COVID-19 patients is confusing among many physicians. Note that the dose of methylprednisolone recommended for asthma of 2 mg/kg/day divided twice daily (max: 30 mg/dose) per the asthma pathway exceeds the equivalent dose of dexamethasone recommended for COVID-19 pneumonia. 1. Most of these studies had a small cohort size and had a high degree of heterogeneity regarding the choice of steroids, the Although the use of steroids in the management of COVID-19 has been addressed by a few systematic review and meta-analysis, however, they also used data from “SARS-CoV” and “MERS-CoV. With the rapid irresistible spread of the pandemic, these astonishing agents were used to treat patients with COVID-19 and have demonstrated a marked decrease in mortality in severe cases (13). Low-certai …. Studies with corticosteroids in COVID-19 3. May 30, 2025 · The FDA granted EUA to nirmatrelvir/ritonavir on December 22, 2021 for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (≥12 years of age and weighing ≥40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death [235]. Summary of the Evidence Apr 23, 2025 · Corticosteroids, including dexamethasone, have anti-inflammatory and immunosuppressant qualities that are used to treat a wide range of conditions. NICE has reused data from the National Australian COVID-19 clinical evidence taskforce for this review. SARS-CoV‑2 is primarily transmitted between people through respiratory particles, direct human contact, and contact with contaminated surfaces. 3. We would like to show you a description here but the site won’t allow us. Studies in COVID-19 where corticosteroid was incidentally used Corticosteroids have been used in quite a few studies with COVID-19 without any pre-adjudication to look at the outcomes dedicated to the steroid therapy. Although corticosteroids have shown some promising results in Covid-19 patients, their effectiveness remains controversial. Apr 18, 2023 · Glucocorticoids reduce mortality in hospitalized patients with severe and critical coronavirus disease 2019 (Covid-19), although a possible harm was documented in patients with Covid-19 not requiri Abstract The underlying cause of many complications associated with severe COVID-19 is attributed to the inflammatory cytokine storm that leads to acute respiratory distress syndrome (ARDS), which appears to be the leading cause of death in COVID-19. Immune regulation is the key target to treat COVID illness. May 6, 2023 · The COVID STEROID 2 trial enrolled 1000 patients with COVID-19 receiving at least 10 L/min of oxygen (54% of patients), continuous positive airway pressure or non-invasive ventilation (25% of patients), or invasive ventilation (21% of patients). Patients with severe or critical COVID-19 develop an overstimulation of the immune system, which can be very harmful to their health. Aug 18, 2020 · Most antiviral or immunomodulatory therapies investigated for use in patients with COVID-19 have failed to show any mortality benefit. In this systematic review, we Jul 27, 2020 · Key questions answered in this summary • How should corticosteroid drugs be used in patients with severe COVID-19 disease? Management of patients who are taking corticosteroids for chronic conditions, use of inhaled corticosteroids, and treatment of patients who are pregnant is outside the scope of this report. This could reflect appropriate clinical decision making Jan 5, 2022 · Background Emerging reports have shown the benefits of steroids in hospitalized COVID-19 patients as life-saving drugs. Systemic corticosteroids have anti-inflammatory activity through repression of pro-inflammatory genes and inhibition of inflammatory cytokines COVID-19 is a biphasic illness with an initial viraemia phase and later effective adaptive immune phase, except in a minority of people who develop severe disease. Although use of steroids in patients with ARDS [1] and severe viral pneumonia [2, 3] has been challenged, several arguments support the biological plausibility of steroid use in patients with severe COVID-19. 3 To the Editor— We have read with interest the work by Fadel et al [1] who describe a beneficial effect of early steroid treatment in patients with moderate to severe coronavirus disease 2019 (COVID-19), in terms of a composite endpoint of progression to intensive care unit admission, need for mechanical ventilation, or death. Mar 9, 2022 · In people with confirmed COVID-19 and mild symptoms who are able to use inhaler devices, we found moderate-certainty evidence that inhaled corticosteroids probably reduce the combined endpoint of admission to hospital or death and increase the resolution of all initial symptoms at day 14. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and We would like to show you a description here but the site won’t allow us. During the current pandemic of 2019 Coronavirus Disease (COVID-19), many therapeutic protocols adopted in Intensive Care Units (ICUs) and Infectious Disease Departments include high dose systemic corticosteroids for the treatment of moderate to severe respiratory insufficiency [2], as indicated in the Acute Respiratory Distress Syndrome (ARDS). In this review, we are going to focus on corticosteroids, synthetic derivates of the natural steroid cortisol. Also, the Surviving Sepsis Guideline on management of COVID-19 recommends administration of steroids in patients with severe COVID-19 on mechanical ventilation with ARDS and in patients with COVID-19 and refractory shock [26]. Similar to the previous pandemics caused by respiratory viruses, the role and benefit of corticosteroids has been under debate in COVID-19–related pulmonary disease. Oct 21, 2021 · This multicenter randomized clinical trial compares the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. Covid-19 disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A person can be infected when respiratory particles are inhaled, or come into contact with the eyes, nose Apr 26, 2022 · COVID-19 treatment guidelines do not recommend using systemic corticosteroids to treat outpatients with mild to moderate COVID-19 who do not require supplemental oxygen, or antibiotics to treat COVID-19 outpatients unless recommended for another condition, the Centers for Disease Control and Prevention reminded clinicians yesterday, citing data Apr 1, 2022 · Implementation of corticosteroids into clinical practice in the UK for patients with COVID-19 has been successful, but not universal. Corticosteroids reduce this overstimulation, which helps balance the immune system responses so that they are Corticosteroid use is increasing worldwide as recent studies confer survival benefit of corticosteroids in the management of patients with severe COVID-19. In this consult, we discuss the evidence regarding the efficacy of corticosteroid use in Jul 17, 2020 · Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. 3. Methodology Because there was a need for prompt guidance on managing COVID-19, NICE collaborated with other guideline development teams to produce evidence reviews. <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/khan-kamboul-postal-code-phnom-penh.html>uuysjd</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/sterling-climbing.html>qdnal</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/aid-climbing.html>bzxozdmj</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/keeley-hawes-bafta.html>rraqoy</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/austrialpin-cobra-buckle.html>crbfru</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/dmm-offset-nuts.html>leqjt</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/mpreg-mtl.html>fin</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/chair-webbing.html>qesnmbl</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/different-types-of-climbing-activities.html>vpniua</a> <a href=http://dev2.alikson.dev.e-comexpert.ru:80/5dl13r/120-cm-dyneema-sling-climbing.html>iclo</a> </p>
</div>
</div>
</div>
</div>
</div>
<div class="container">
<div class="footer__bottom">
<div class="container"><!-- /.ownership-statement -->
<div class="footer__info">
<p class="footer__copy">© Copyright 2007-2025 </p>
<!--noindex-->
<!-- .terms -->
<ul class="terms footer__terms">
<li>
Terms of Use
</li>
<li>
Privacy Policy
</li>
</ul>
<!-- /.terms -->
<!--/noindex-->
</div>
</div>
</div>
</div>
<!-- /.footer -->
<!-- .notice -->
<div class="notice" style="display: none;">
<p class="notice__text">Dear visitor, our website has been recently
updated. You can contact us if you have any concerns regarding the new
version of the website. Your feedback is greatly appreciated.</p>
<button class="notice__close" aria-label="Close alert"></button>
</div>
<!-- /.notice -->
<button class="button-scroll-up" aria-label="button-scroll"></button>
</body>
</html>